NINLARO is the first and only oral medication of its kind, a proteasome inhibitor, that may help people when their multiple myeloma comes back. In a study of multiple myeloma patients whose disease …

May 20, 2025 · Ninlaro is a cancer medicine used to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone.

May 23, 2024 · In 2015, the U.S. Food and Drug Administration approved NINLARO® (ixazomib) for the treatment of adult patients with myeloma who have received at least 1 prior therapy. Ninlaro is the …

NINLARO in combination with lenalidomide and dexamethasone is an approved treatment for relapsed multiple myeloma after at least 1 previous therapy, including indolent relapsed multiple myeloma. …

Oct 6, 2024 · Ninlaro (ixazomib) is commonly used to treat a blood cancer called multiple myeloma. Ninlaro may also be used for other conditions as determined by your healthcare provider.

Ninlaro is an anti-cancer drug and a member of a class of drugs called proteasome inhibitors. Ninlaro is believed to work in cases of myeloma by interfering with cell division.

Ninlaro (ixazomib) is a proteasome inhibitor used with lenalinomide and dexamethasone for adults with multiple myeloma who received prior therapy. See its full prescribing information.

Aug 1, 2024 · Ninlaro (Ixazomib Capsules) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.

4 days ago · Patients with multiple myeloma are at significantly increased risk of venous thromboembolism (VTE), particularly in the first year after diagnosis.

5 days ago · NINLARO is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID ® (lenalidomide) and dexamethasone, in people who have received at least …